IP Library Granted Patent US 10,226,493
Granted Patent B2
US 10,226,493 · App. 13/876,070 · Granted Mar 12, 2019

Patent

Inventors: Allan Sik Yin Lau (Hong Kong, CN); Stanley Chi Chung Chik (Hong Kong, CN); Anna Hing-Yee Law (Hong Kong, CN); Cindy Lai Hung Yang (Hong Kong, CN)
Assignees: BAGI RESEARCH LIMITED; VERSITECH LIMITED
A61K36/07A61K2236/333Y02A50/463
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,226,493
App. No.
13/876,070
Granted
Mar 12, 2019
Kind
B2
Abstract

The subject invention provides Coriolus versicolor extracts, pharmaceutical compositions comprising the Coriolus versicolor extracts, methods of preparation, and therapeutic uses thereof. Advantageously, the subject Coriolus versicolor extract has immunomodulatory, anti-tumor, anti-microbial, and antiviral effects. In a preferred embodiment, the subject invention can be used to inhibit the metastatic spread of cancer cells. In certain preferred embodiments, the subject invention can be used to treat glioblastoma multiforme, nasopharyngeal carcinoma, breast carcinoma, lung carcinoma, prostate cancer, and colon carcinoma, as well as bacterial, viral, fungal, protozoan, and/or other microbial infection.

Claims (15)

1. A method for treating a disease or condition selected from brain tumors; nasopharyngeal carcinomas; breast cancer; lung cancer; leukemia; lymphoma; colon cancer; stomach cancer; esophageal cancer; bladder cancer; gastric cancer; glioblastoma multiform; prostate cancer; and viral, bacterial, protozoan, fungal and microbial infections where the modulation of an immune response would be beneficial, wherein said method comprises administering, to a subject in need of such treatment, an effective amount of a composition comprising a Coriolus versicolor extract obtained by either:

A) a method comprising the steps of:

a) providing a sufficient quantity of raw material of Coriolus versicolor ; and

b) extracting biologically-active chemical constituents from the raw material of Coriolus versicolor with a polar solvent that is about 95% ethanol at a temperature of about 15° C. to about 30° C. to yield a Coriolus versicolor ethanol extract and a residue, and recovering the Coriolus versicolor ethanol extract;

wherein step b) is performed once or more than once; or

B) a method comprising the steps of:

a) providing a sufficient quantity of raw material of Coriolus versicolor;

b) extracting biologically-active chemical constituents from the raw material of Coriolus versicolor with a polar solvent that is about 95% ethanol to yield a Coriolus versicolor ethanol extract and a residue, and recovering the Coriolus versicolor ethanol extract, wherein step b) is performed once or more than once;

c) extracting the residue obtained in step b) with an aqueous alkaline solution to yield an aqueous extract, and recovering said aqueous extract, wherein step c) is performed once or more than once; and

d) combining one or more extracts obtained from steps b) and c) to yield Coriolus versicolor extract.

2. The method, according to claim 1 , used to reduce IL-10 production and/or increase IFNβ production.

3. The method, according to claim 1 , used to treat a brain tumor, nasopharyngeal carcinoma, breast cancer, lung cancer, leukemia, lymphoma, colon cancer, stomach cancer, esophageal cancer, bladder cancer, or gastric cancer.

4. The method, according to claim 1 , used to treat glioblastoma multiforme, nasopharyngeal carcinoma, breast carcinoma, lung carcinoma, prostate cancer, or colon carcinoma.

5. The method, according to claim 1 , used to treat infection by human immunodeficiency virus (HIV), influenza A virus, influenza B virus, human T-lymphotropic virus Type I (HTLV-1), bovine leukemia virus (BLV), Epstein-Barr virus, coronavirus, mycobacteria, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichii coli, Listeria monocytogenes, L. amazonensis, Pneumocystis, Toxoplasma, Candida , and/or Aspergillus.

6. The method, according to claim 1 , used to treat infection by herpes simplex virus, varicella zoster, cytomegalovirus, and/or herpes virus-8.

Assignments (1)
CHANGE OF NAME Recorded Nov 16, 2015
From: PURAPHARM COMPANY LIMITED
To: BAGI RESEARCH LIMITED
Reel/Frame 037043/0842 →
Continuity (3)
Provisional Application 61390279 · Oct 6, 2010
Provisional Application 61432853 · Jan 14, 2011
Related Publication 20140017275A1 · Jan 16, 2014